Researchers shed light on the "dark matter" of the gut, revealing a species of fungus that could potentially help counter ...

GSK will buy efimosfermin, a liver disease drug in late-stage trials, for up to $2 billion from U.S. biotechnology firm ...

A groundbreaking study from the University of Oklahoma reveals that the hormone FGF21 can reverse fatty liver disease by ...

The new acquisition from Boston Pharmaceuticals adds to a wave of dealmaking undertaken by GSK to build its liver disease ...

New research reveals that semaglutide significantly improves liver health in MASH patients. A new study published in the New ...

GSK acquires Boston Pharmaceuticals' efimosfermin for up to $2 billion, targeting liver diseases like MASH and ALD.

GSK is set to acquire efimosfermin, a promising liver disease drug, from Boston Pharmaceuticals for a potential $2 billion.

Just a day after dropping a $625m cancer asset, GSK has inked a deal worth a potential $2bn to acquire Boston Pharmaceuticals ...

Under the agreement, GSK will acquire BP Asset IX, a subsidiary of Boston Pharmaceuticals, for up to $2 billion in total cash ...

GSK plans to purchase an experimental drug for the liver disease MASH from Boston Pharmaceuticals for $1.2 billion upfront.

GSK has agreed to pay $1.2 billion upfront to acquire rights to efimosfermin from Cambridge, Massachusetts-based Boston ...